Testing a new protein drug with standard treatment for new glioblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your glioblastoma has been newly diagnosed and confirmed by pathology (tissue testing).
- You can do daily activities fairly well (Karnofsky score 70% or higher).
- Your HIV, hepatitis B, and hepatitis C tests are negative (or hepatitis C is not active).
- If you can become pregnant, you must have a negative pregnancy test and use highly effective birth control; if you’re a man who can father children, you must use two birth-control methods during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial is for people with newly diagnosed glioblastoma who have finished standard chemoradiation. It tests whether adding a drug called flazoparib to the usual chemotherapy (temozolomide) can help prevent the cancer from coming back. Researchers will check safety and how well the combination works.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.